197 related articles for article (PubMed ID: 10546469)
1. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
[TBL] [Abstract][Full Text] [Related]
2. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.
Di Lorenzo G; Morici G; Drago A; Pellitteri ME; Mansueto P; Melluso M; Norrito F; Squassante L; Fasolo A
Clin Ther; 1998; 20(6):1130-48. PubMed ID: 9916607
[TBL] [Abstract][Full Text] [Related]
4. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
Paggiaro PL; Giannini D; Di Franco A; Testi R
Eur Respir J; 1996 Aug; 9(8):1689-95. PubMed ID: 8866596
[TBL] [Abstract][Full Text] [Related]
5. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
Wiegand L; Mende CN; Zaidel G; Zwillich CW; Petrocella VJ; Yancey SW; Rickard KA
Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.
Nutini S; Martini T; Righi R
Respir Med; 1998 Apr; 92(4):683-90. PubMed ID: 9659537
[TBL] [Abstract][Full Text] [Related]
7. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Ulrik CS
Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.
Fjellbirkeland L; Gulsvik A; Palmer JB
Respir Med; 1994 Sep; 88(8):599-607. PubMed ID: 7991885
[TBL] [Abstract][Full Text] [Related]
10. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
Ulrik CS
Ugeskr Laeger; 1996 Jun; 158(25):3604-7. PubMed ID: 8693619
[TBL] [Abstract][Full Text] [Related]
11. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Boyd G
Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
[TBL] [Abstract][Full Text] [Related]
13. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
14. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
15. Salmeterol versus theophylline in the treatment of asthma.
Pollard SJ; Spector SL; Yancey SW; Cox FM; Emmett A
Ann Allergy Asthma Immunol; 1997 May; 78(5):457-64. PubMed ID: 9164358
[TBL] [Abstract][Full Text] [Related]
16. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
Cazzola M; Vinciguerra A; Di Perna F; Matera MG
Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
[TBL] [Abstract][Full Text] [Related]
17. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
Davies B; Brooks G; Devoy M
Respir Med; 1998 Feb; 92(2):256-63. PubMed ID: 9616522
[TBL] [Abstract][Full Text] [Related]
19. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
Wilson AJ; Gibson PG; Coughlan J
Cochrane Database Syst Rev; 2000; (2):CD001281. PubMed ID: 10796631
[TBL] [Abstract][Full Text] [Related]
20. [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases].
Beeh KM; Wiewrodt R; Salem AE; Buhl R
Pneumologie; 2000 Jun; 54(6):225-31. PubMed ID: 10934892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]